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Immunohistochemical Quantification of Heparan 
Sulfate Proteoglycan and Collagen IV in Skeletal 
Muscle Capillary Basement Membranes of Patients 
With Diabetic Nephropathy
Hiroki Yokoyama, Poul E. H0yer, Pernille M. Hansen, Jacob van den Born, Tomiy Jensen, Jo H.M. Berden, 
Torsten Deckert, and Charly Garbarsch
In IDDM patients, an increased permeability of the 
glomerular capillaries has been associated with a gen­
eral loss of negatively charged heparan sulfate proteo­
glycans (HSPGs) within basement membranes (BMs). In 
the present study, we used immunohistochemical stain­
ing to quantify heparan sulfate (HS), HSPG core pro­
tein, and collagen IV in capillary basement membranes 
of skeletal muscle biopsies taken from 9 healthy control 
subjects (C) and 20 IDDM patients: 7 with normal albu­
min excretion rate (<30 mg/24 h) (D0), 5 with incipient 
nephropathy (albumin excretion rate 30-300 mg/24 h) 
(Di), and 8 with clinical nephropathy (albumin excre­
tion rate >300 mg/24 h) (D2). In the capillaries, stain­
ing was measured by a scanning and integrating 
microspectrophotometer. A significant difference in 
the absorbance of HS was found among the four sub­
groups (means ± SD): 0.477 ± 0.082 (C), 0.627 ± 0.031 
(D0), 0.542 ± 0.098 (Dx), and 0.371 ± 0.118 (D2) (P = 
0,006). Similarly, an overall significant difference in 
the absorbance of collagen IV was demonstrated 
(means ± SD): 0.836 ± 0.111 (C), 0.838 ± 0.300 (D0), 
0.970 ± 0.173 (Dx), and 0.512 ± 0.248 (D2) (P = 0.02). No 
statistical difference in the absorbance of core protein 
was demonstrated among the groups. Within the dia­
betic groups, IIS was inversely correlated to albumin­
uria (r = -0.76, P = 0.003) and albuminuria corrected for 
creatinine clearance (r = -0.69, P s 0.008). Because, in 
IDDM patients with albuminuria, alterations of the 
content of HS and collagen IV within the capillary BM 
have been demonstrated immunohistochemically, not 
only in the glomerular filtration barrier, but also in the 
skeletal muscle capillary BM, we suggest that these 
changes reflect universal quantitative or qualitative 
alterations within the capillary filtration barrier. 
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'à
ccording to the Steno hypothesis (1), in IDDM 
patients, albuminuria reflects not only severe 
renal disease, but also a generalized vascular 
JL *  J ^ i  dysfunction, demonstrated by increased cardio­
vascular morbidity and mortality (2,3). The nature of such uni­
versal alterations is unknown, and might be due to both 
increased capillary pressure (4) and structural alterations of 
the macromolecular pathway between the capillary lumen 
and the lymphatic capillaries (i.e., the extracellular matrix 
[ECM]) (5). Within the ECM, heparan sulfate proteoglycans 
(HSPGs) constitute a major class of proteoglycans that are 
found especially in basement membranes (BMs). HSPGs are 
formed by a central core protein to which the anionic gly- 
cosaminoglycan heparan sulfate (HS) is linked (6),
In diabetic nephropathy, renal pathobiochemical alter­
ations are characterized by accumulation of BM-like mate­
rial within the glomeruli (7) and a decreased number of 
anionic sites (Le., HS or HSPG) within the glomerular base­
ment membrane (GBM) (7-12). In rats, loss of GBM-HS 
induces albuminuria (13), and in humans a negative corre­
lation between urinary albumin excretion rate (AER) and the 
content of HS within the GBM has been demonstrated (12). 
However, patients with diabetic nephropathy suffer from not 
only increased macromolecular permeability within the 
glomeruli, but also an increased extrarenal capillary per­
meability, as indicated by a 50% increase of the transcapil­
lary escape rate of albumin and other plasma proteins 
(14,15)* Therefore we hypothesized that deficiency of HS, 
both in glomeruli and in the vessel walls of extrarenal tissue, 
is the common link between albuminuria and macrovascu- 
lar disease in diabetic patients with nephropathy. The aim 
of the present study was to evaluate possible alterations of 
the amount of HS in extrarenal tissue among healthy sub­
jects and IDDM patients with and without albuminuria. We 
performed a quantification of HS, HSPG core protein, and 
collagen IV by immunohistochemistry on the BMs of skele­
tal muscle capillaries.
RESEARCH DESIGN AND METHODS
Subjects. Nine healthy control subjects (C) and twenty IDDM patients partici­
pated in the study. The diabetic patients were recruited from the outpatient clinic 
of the Steno Diabetes Center, and the control subjects were selected from the same 
geographic area. All IDDM patients had diabetes diagnosed before age 31 years. 
Diabetes duration was >10 years. All patients, except one, were on insulin treat-
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PIG. 2. A: abNorbanee of IIS, ★, P < 0.006 among all groups; *★, P = 
0.01 among diabetic groups, /i: absorbance of collagen IV. ★, P = 0.02 
among all group«; ★★,ƒ*» 0.03 among diabetic groups. C: absorbance 
of HSPG. ★ , P ~ 0.12 among all group« and diabetic groups. Within sub­
groups, the box-arid-whisker plot estimate« the median, upper, and 
lower quartiles and the range; points estimate tlic mean value in indi­
vidual subjects.
1:48000. The sections were incubated overnight at 4U0. After being washed in three 
changes (5 inin cadi ) of TBS, secondary antibodies dilut ed 1:250 (biotinylated anti- 
mouse IgM antibody’) and 1:200 (biotinylated rabbit anti-mouse IgG antibody) were 
added; the sections were then incubated for 30 min. Another three changes (5 min 
cacti) in TBS wen* performed. after which the sections were incubated for 30 min 
with alkaline phosphatase-conjugated avidiu according to the manufacturer’s 
proscription (K0Ü70; Dakopatts). This was followed by throe changes (5 min 
each) in TBS. Finally, alkaline phosphatase activity was revealed by development 
for 20 min in 5-bromo-4-chloro-induJy] phusphate/nitroblue tét razolium medium 
containing 1 mmol/l levamisole (Sigma, St. Louis, MO). The medium was prepared 
by mixing the following solutions: 10 ml predotection buffer (100 miuol/1 Tris buffer 
[pi I 8.N], 5 uuuol/l MgCL and 100 mmol/1 NaCl), 20 pi 54)romo4-chloro4udolyl 
phosphate solution (BCÏP; 10 mg BC1P [Sigma, St. Louis, MO] in 200 pi NfN- 
dinietliylformamide) and 140 pi nitrobhie tétrazolium solution (NET; 15 mg NBT 
[Sigma, St. Louis, MO] in 200 pi N, iV-dimethylformamide).
All procedures for collagen IV, IIS, and HSPG (‘ore protein for all subjects were 
performed in one sett ing,
Quantitative procedure. A minimum of 40 muscle capillaries cut in cross sec­
tion and located between at least three adjacent; muscle fibers (e.g., Fig. LA) 
were randomly selected from at least two sections on slides with the same code. 
If it was impossible to identify 40 capillaries for quantification, the specimen was 
excluded. A randomly selected area of the stained BM in each of the capillaries 
was scanned with a Vickers M85A scanning and integrating microspectropho- 
lomoter (Vickers, York, U.K. ) with the following machine sellings: x 100 objective 
(scanning area J.î.l pur), light, at the isobestic wavelength (585 run) of NBT for­
malins, and a scanning spot diameter of 0.2 pm. Within each area, the individual 
spot readings were automatically integrated by the instrument. The mean inte­
grated absorbance over all areas was then calculated by reference to a standard 
calibration graph constructed by measuring a series of neutral density Alters 
with known absorbance values. Because this procedure was performed on each 
experimental day, any day-to-day variation in the sensitivity of the mlerospeo 
trophotometer was eliminated. Moreover, measurements of the neutral density 
fillers showed that the instrument was linear within the range of absorbance val­
ues recorded in the capillaries. Finally, the mean fonuazau deposition measured 
in the absence of the primary antibody was subtracted from that measured in the 
presence of antibody to give a measure (± SD) of the specific antibody binding 
alone.
Metabolic control and renal function. HbA1(. was measured by high-perfor­
mance liquid chromatography (Bio Rad DIAMAT, Richmond, C’A; normal range
Blood glucose was measured by means ofllypocount; B (Hypoguard 
LI), Wbodhridge, Suffolk, U.K.). Serum and urinary creatinine was measured by 
a kinetic Jaffe’s method (interassay coefficient of variation <5%). Urinary albumin 
concentration was determined using an enzyme-linked immunosorbent assay 
method (intra- and interassay coefficient of variation <0%) (17). In «Habetic 
nephropathy, the glomerular nitration rat e and creat inine clearance show a strong 
inverst1 correlation with the percentage of occluded and globally sclerosed 
glomeruli (18). We therefore corrected the albuminuria (mg/24 h) for the creati­
nine clearance (ml/min), yielding a ratio expresseil in pg/ml (Thble 1). This ratio 
of albuminuria reflects the albumin nitration in still-functioning glomeruli (12). 
Statistical analyses. The slides were decoded at the end of the experiment. Data 
were processed using the Sl at Graphics st atistical software package (STSC, 
Rockville, MD) and Unislat for Windows (Unistat, London, U.K.). Results are 
expressed as means t  SI), except, for results from AER. AEU was not normally 
distributed, anti the results are therefore given as median and range. Differences 
between groups were assessed by unpaired Kruskal-Wallis tests. Correlations were 
expressed by Spearman’s correlation coefficients (r). P values <0.05 were 
accepted as significant.
RESULTS
Clinical characteristics of the study groups are given in Table 
1. The diabetic groups were comparable regarding age, diabetic 
duration, daily insulin dosage, and BMI, Among diabetic 
patients, systolic and diastolic blood pressure was signifi­
cantly higher in patients with albuminuria. A similar increase 
was observed for HbAu., although it was not significant.
Because of the exclusion criteria related to the quantitative 
analysis, HS, HSPG core protein, and collagen IV were quan­
tified in an unequal number of subjects. HS was quantified in 
24 subjects. An overall significant difference was found 
among the four subgroups (P < 0.006) and among the diabetic 
groups (P = 0.01; Fig. 2A). This was mainly due to an increase 
in HS absorbance within the normoalbuminuric group of
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FIG. 3. HS absorbance versus albuminuria/creati­
nine clearance (pgAul) in patients with IDDM (n = 
16, creatinine clearance is missing in 1 patient); r = 
-0.69, P = Ö.008.
IDDM patients and a reduction of HS absorbance in the clin­
ical nephropathy patients: 0.477 ± 0.082 (C), 0.627 ± 0.031 (D0), 
0.542 ± 0.098 (Dj), and 0.371 ± 0,118 (D2). Within the diabetic 
patients, a significant inverse correlation between HS 
absorbance and albuminuria (r = -0.76, P = 0.003) or albu­
minuria corrected for creatinine clearance (r = -0.69, P = 
0.008; Fig. 3) was observed.
Collagen IV was quantified in 28 subjects. An overall sig­
nificant difference in absorbance was found among the four 
subgroups (P =s 0.02) and among the three diabetic groups (P 
= 0.03; Fig. 2B), This was mainly due to a decrease of colla­
gen IV within the group of patients having clinical nephropa­
thy: 0.836 ± 0.111 (C), 0.838 ± 0.300 (D0), 0.970 ± 0.173 (D,), 
and 0.512 ± 0.248 (D2). Within the diabetic group, collagen IV 
absorbance revealed a significant inverse correlation with 
albuminuria corrected for creatinine clearance (r - -0.57, P 
= 0.02). The coefficient of variation was 3.5, 2.2, and 2,8%, 
respectively, when three sections stained for collagen IV 
were measured on each of 10 days.
HSPG core protein was quantified in 28 subjects. Among the 
groups no significant difference in absorbance was revealed:
0.985 ± 0.150 (C), 0.868 ± 0.146 (D0), 1.126 ± 0.24 (Dj), and
0.894 ± 0.097 (D2) (P = 0.12; Fig. 2Ç).
No correlation between HS absorbance and HbAlc, post­
prandial blood glucose, or diabetes duration was demon­
strated in the entire population or within the diabetic groups. 
Also, the absorbance of collagen IV and HSPG core protein 
was unrelated to HbAlc. Furthermore, if the diabetic sub­
jects enrolled for the measurements of HS, collagen IV, or 
HSPG core protein absorbance were stratified into two 
groups defined by a HbAlc level above or below the median 
value, no significant difference in absorbance was demon­
strated between groups.
D ISCU SSION
Previously, a comparable decrease of GBM-HS or HSPG 
core protein has been demonstrated in diabetic kidney dis­
ease, although the results have been restricted by the use of 
semiquantitative analysis (7,9,10,12), In the present study, a 
reproducible quantitative immunohistochemical analysis
was used to estimate the concentration of HS, HSPG core 
protein, and collagen IV within capillary BMs of skeletal 
muscle biopsies. The present data document for the first 
time an extrarenal reduction of capillary BM-HS in patients 
with diabetic nephropathy.
Such an alteration of BM-HS absorbance in IDDM patients 
may be explained by altered antibody-epitope interaction. 
Recently, we showed that the JM403 binding to HS is depen­
dent on the presence of an N-unsubstituted glucosamine unit 
in HS, and that the JM403 epitope expression in HS prepara­
tions from various sources is inversely correlated with HS sul­
fation (19). The HS chains are modified posttranscriptionally 
by N-substitution of the glucosamine units, facilitated by the 
key enzyme glucosaminyl N-deacetylase/N-sulphotransferase. 
This enzyme has been found to be decreased in both diabetic 
animals (20,21) and diabetic patients (22). Thus, in the pre­
sent study, the increase of HS absorbance in the D0 group 
might be related to an undersulfation of HS. Consequently, our 
finding of decreased HS absorbance in patients with albu­
minuria might be explained by oversulfation of HS; that is, a 
decrease in the number of N-unsubstituted glucosamine units 
of HS or a decreased content of HS in the BM of muscle cap­
illaries. Along the same line, our observation of decreased 
absorbance of HS in the D2 group might be due to an absolute 
decrease of HS within muscle capillary BM, as was previously 
demonstrated in the GBM of diabetic patients with albumin­
uria (11). We therefore suggest that the first change in HSPG 
in diabetes is probably an undersulfation of HS (the D0 
group), followed by an absolute decrease of HS (the Dx and 
D2 groups), as has been discussed previously (23). An 
absolute reduction of BM-HS could be genetically deter­
mined. Thus an altered gene transcription or posttranscrip- 
tional modification of the first domain within the HSPG2- 
gene coding for the amino acid sequence at the protein HS- 
attachment sites (24) could be responsible for the observed 
“loss” of HS. Such a qualitative alteration within the HSPG 
core protein might not have been detected in the present 
quantification.
Theoretically, the reduced quantity of HS could be due to 
masking of epitopes, either by nonenzymatic glycation of the
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primary amino group on IIS recognized by JM403, or by 
increasing amounts of other BM proteins, such as collageus, 
laminin, or fibronectin (7,9), perhaps induced by transforming 
Growth faetor-ß overexpression (25). Thus it has been inter­
preted that structural changes in the GBM prevent the normal 
organization of HSPG, making it inaccessible to specific anti­
bodies (2(5), and thereby blurring the use' of imnumohisto- 
chemistry to draw conclusions about quantitative changes in
macromolecular compositions. In the present study, the influ­
ence of nonenzymatie glycation seems to be negligible, since 
IIS absorbance did not correlate with metabolic regulation. 
Also, a relationship bet ween collagen IV and a reduction of I IS 
seems unlikely, given that a concomitant decrease of both 
molecules was found in diabetic patients with nephropathy. 
This is in agreement, with the findings of Tamsma et al (12), 
who studied the GI1M of IDDM patients with advanced 
nephropathy, but., disagrees with findings from other studies in 
which increasing amounts of GBM-collagen IV in diabetic 
patients with albuminuria were reported (7,9,27). Conflicting 
results might be due to the inclusion of patients with different 
degrees of albuminuria, since it, has been demonstrated that; 
collagen IV expression is increased in the early stage of dia­
betic nephropathy and decreased in more advanced stages
(28,29). Further, different results might be obtained due to the 
use of anti-collagen IV antibodies with different specificities 
(directed against either w ,/u.» or a/u,,). We used a commercial 
monoclonal anti-collagen IV antibody in which the specific 
binding sites have' not been identified.
In accordance with two former studies, we demonstrated 
that the content of BM-HS in muscle capillaries is inversely 
correlated to the degree of albuminuria (9,12), Because an 
increased glomerular leakiness of albumin in diabetic 
patients has been related to an increased systemic transcap­
illary albumin escape rate (14), we interpret our data as sup­
porting the hypothesis of a funct ional relationship bet ween 
a decreased content of BM-IIS and a general increased trans» 
capillary escape rat e' of albumin ( 1 ), although in the present 
study the latter could not be measured. In addition, our data 
demonstrated an inverse correlation between collagen IV 
absorbance and albuminuria corrected for creatinine clear­
ance, thereby indicating that , besides HS, changes in collagen 
IV might also contribute to an enhanced diabetes-related
ECM permeability.
Acknowledging that capillary wall transport involves 
mechanisms other than charge-electrostatic interactions in 
BMs (30), the major impact of t he present study is that, using 
the same primary ant ibodies, a similar reduction in BM-HS of 
muscle capillaries and GBM-HS (12) is observed in IDDM
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